• The BsmI polymorphism of the vitamin D receptor (VDR) gene influences mineral metabolism and the course of cancers and infections. The poly-A polymorphism is in linkage disequilibrium with BsmI and could be responsible for clinical associations attributed to BsmI. The objective of this work is to study the influence of VDR polymorphisms on survival of 143 prevalent hemodialysis (HD) patients followed up for 4 years. Chi-square test was used to study the association between survival and these polymorphisms. Cox analysis was performed, adjusting for comorbid conditions in the entire HD population, groups of patients on HD therapy for less than 5 and 3 years before entering 4 years of observation, patients without diabetes, and patients treated with calcitriol. 
I
T IS WELL ESTABLISHED that vitamin D is a potent immunomodulator. Lower vitamin D levels have been associated with poorer prognosis in human immunodeficiency virus-infected patients 1,2 and a greater occurrence of tuberculosis in exposed patients. 3 Demonstration of the inhibitory role of 1,25-dihydroxyvitamin D 3 in experimental autoimmune diseases [4] [5] [6] [7] and the fact that it has been proven to prolong allograft survival 8 are evidence of the importance of 1.25-dihydroxyvitamin D 3 in the immune system. Moreover, receptors for 1.25-dihydroxyvitamin D 3 have been found in human peripheralblood monocytes and active lymphocytes of rats and humans. [9] [10] [11] [12] In addition, vitamin D has an antiproliferative and differentiating effect, shown in vitro in various cell lines that express vitamin D receptor (VDR), such as breast cancer cells. 13, 14 In humans, an inverse relationship between vitamin D level and tumor cell growth has been reported. 14 Recently, an association was described between 3ЈVDR gene polymorphisms and the prevalence 15, 16 and aggressiveness of prostate 15 and breast 17 cancers and the prevalence of certain immune diseases, such as type 1 diabetes mellitus 18, 19 and systemic lupus erythematosus. 20 Antiproliferative properties of vitamin D also have been shown in the cardiovascular system. In vitro, 1,25-dihydroxyvitamin D 3 inhibits vascular smooth muscle cell growth, 21 and both vitamin D and retinoic acid reduce endothelininduced secretion of atrial natriuretic peptide. 22 On a clinical level, calcitriol treatment reduced left ventricular hypertrophy in hemodialysis (HD) patients. 23 HD patients begin to show a relative deficiency of 1,25 dihydroxyvitamin D 3 from early stages of chronic renal failure, 24, 25 and this may be influenced by BsmI VDR gene polymorphisms. 25 Therefore, enough evidence exists to hypothesize that lower levels of 1,25-dihydroxyvitamin D 3 or variations in VDR function induced by polymorphisms at the 3Ј and 5Ј regions of the VDR gene may have a role in the elevated mortality rate of these patients. The aims of the present study are: (1) to analyze the influence of VDR gene polymorphisms on the mortality of HD patients, and (2) to ascertain whether previous treatment with calcitriol might modify such influence.
MATERIAL AND METHODS

Patients
This prospective study includes the prevalent HD population of Lleida, Spain, on January 1, 1996, without exclusion criteria. Lleida is a region situated in Catalonia, in northeastern Spain (41°37Ј N; yearly average 7.6 hours/d of insolation). The basic health area covered 341,152 inhabitants in 1996. The population studied was composed of 143 patients (80 men, 63 women; mean age, 61.9 years; 95% confidence interval [CI], 59.5 to 64.3) who were alive and on HD therapy at the start of the follow-up period. All patients were white and are a representative sample of the HD population in Catalonia. The incidence of chronic renal failure, presence of comorbid conditions, and underlying causes of renal failure in the patients were the same as for the rest of the region (Catalonia Renal Patients Database). HD patients in Catalonia are a relatively homogeneous population. Compliance with treatment approaches 100%, and characteristics of the HD prescription also follow similar guidelines regardless of the HD center. Mortality rates during the years before the start of the study did not present important variations (1995, 9.6%; 1994, 7.8%; 1993, 8.6%; 1992, 8.6%; and 1991, 8.2%). Patients had been on HD therapy for 1,671 days (95% CI, 1,403 to 1,938) before the start of the study, and 95% of patients underwent dialysis for 4 hours three times weekly (90%, standard cellulosic dialyzers; 10%, high-permeability polymethylmethacrylate or polyacrylonitrile dialyzers). Target Kt/V was 1.1 to 1.2, and actual reached KT/V was 1.19 (Table 1) .
One hundred fourteen patients were on calcitriol treatment during the year before initiating the study. Calcitriol was administered at doses of 0.25 to 0.5 g post-HD sessions when parathyroid hormone (PTH) levels were greater than 20 pmol/L, with calcium levels less than 10.5 mg/dL after correcting phosphorus levels. If PTH levels decreased to less than 20 pmol/L or the calcium ϫ phosphorus product exceeded 70, calcitriol therapy was stopped. None of the 114 patients had calcitriol treatment discontinued for more than 1 month. Such patients were considered calcitriol treated. Calcium compounds were the phosphorusbinding agents of choice, and aluminum hydroxide was seldom administered. All patients had serum aluminum levels less than 40 g/L. No patient was administered an anticonvulsant, steroid, or immunosuppressant drug or vitamin supplements. Follow-up lasted from January 1, 1996, to January 1, 2000. All patients gave informed consent.
VDR Genotyping
Genomic DNA was extracted from peripheral-blood lymphocytes by a KG-Midi extraction kit (Camgen, Cambridge, UK) and used in polymerase chain reaction protocols to amplify previously described VDR polymorphisms. Two restriction fragment length polymorphisms, defined by the restriction endonucleases FokI and BsmI, and a poly-A microsatellite were genotyped on this study. Primer sequences were as follows: primers hvdr3 (5Ј-AGC GTC CAG GCG ATT CGT AG-3Ј) and hvdr4 (5Ј-ATA GGC AGA ACC ATC TCT CAG-3Ј), which amplify a 192-bp fragment surrounding the BsmI polymorphic site, 26 and primers vdr2a (5Ј-AGC TGG CCC TGG CAC TGA CTC TGC TCT-3Ј and vdr2b (5Ј-ATG GAA ACA CCT TGC TTC TTC TCC CTC-3Ј), which amplify a 265-bp fragment surrounding the FokI polymorphic site. 27 Primers 186polyAF (5Ј-CAG TTT GGG AGG TCG AGG TA-3Ј) and 186polyAR (5Ј-CCT GGG TTC AAT TCT TCT GC-3Ј) were designed to amplify a 178-to 188-bp fragment surrounding the poly-A microsatellite site.
Cycling conditions were 96°C for 5 minutes in all reactions, followed by 35 cycles at 94°C for 30 seconds, 65°C for 45 seconds, and 72°C for 45 seconds (BsmI and FokI) or 40 cycles at 94°C for 30 seconds, 63.5°C for 30 seconds, and 72°C for 30 seconds (poly-A microsatellite). A final extension step of 72°C for 10 minutes was applied in all reactions. FokI-and BsmI-amplified fragments were obtained in a single polymerase chain reaction tube, and alleles were detected by single-strand conformation polymorphism analysis. 23 Patterns corresponding to the presence of a given restriction site were assigned by lower case (f and b for FokI and BsmI, respectively).
Amplified fragments for the poly-A microsatellite were resolved in nondenaturing 12% polyacrylamide gels (30:0:8 acrylamide/bis ratio; Hoefer Pharmacia-Biotech, San Francisco, CA) and run in 1 ϫ Tris-borate EDTA (TBE) at a constant 250 V at room temperature for 4 hours. After electrophoresis, gels were silver stained. 26 Poly-A microsatellite fragments define two alleles named small (S), which contains 12 to 15 poly-A tracts (fragment size, 178 to 181 bp), and large (L), which contains 18 to 22 poly-A tracts (fragment size, 184 to 188 bp). To confirm poly-A tract length, sequence analysis of poly-A microsatellite fragments of representative individuals for each genotype was performed by Thermo Sequenase II dye terminator cycle sequencing (Amersham Pharmacia Biotech, Barcelona, Spain) in an ABI Prism Genetic Analyzer (Perkin Elmer Biosystems, Madrid, Spain), following the instructions of the manufacturer.
Biochemical and Clinical Data
Biochemical and clinical data were obtained from patients' medical records. Values included in the analysis were mean values of the quarterly determinations recorded during the year before the start of the study. All biochemical determinations were performed at the same laboratory. Serum intact PTH concentrations were measured by a two-site chemiluminometric assay (normal range, 1.2 to 5.6 pmol/L; intra-assay and interassay coefficients of variation, 5% and 6%, respectively). All blood collections were performed in a fasting state before the start of the second HD session of the week.
Statistical Analysis
Hardy-Weinberg equilibrium was tested by comparing expected and observed genotype frequencies using chisquare test. Linkage disequilibrium was evaluated using standard log likelihood methods. The expectation-maximization (E-M) algorithm was used to obtain the maximum likelihood estimates of standardized disequilibrium coefficient (DЈ). 28 Cox proportional hazard regression techniques were used to estimate the relationship between genotype and survival. An initial Cox model (model 1) was applied to the total HD population, including BsmI, FokI, and poly-A polymorphisms as covariables. Adjustments were made for age; sex; serum calcium, phosphorus, and albumin levels; PTH group; calcitriol treatment; Kt/V; and the presence of comorbid conditions (ischemic heart disease, diabetes mellitus, and hepatitis C virus antibodies). Because PTH has a bimodal effect in such a way that patients with extreme values might be at increased risk for cardiovascular calcifications and cardiovascular morbidity, it was entered as a categorical variable. Thus, patients were assigned to one of the following groups: low-PTH group (PTH Ͻ 12 pmol/L), medium-PTH group (PTH, 12 to 50 pmol/L), and high-PTH group (Ͼ50 pmol/L). To avoid bias caused by possible interactions between age and other variables, the entire population was stratified by sex, age was introduced at the first step, and the rest of the variables were introduced in successive steps. Because the study design was transversal and included the complete prevalent HD population at the time, bias from previous time on HD therapy could be a risk. This was minimized by (1) including previous time on HD therapy as one of the variables in all Cox models, and (2) also analyzing separately patients who had been on HD therapy for less than 5 (model 2; n ϭ 96) and 3 years (model 3; n ϭ 72). Three years was the time chosen because it corresponds to the mean survival in the entire HD population. Because diabetes and calcitriol treatment showed significant influence on survival in this analysis, the importance of these Survival was analyzed using the Kaplan-Meier method in the three BsmI genotypes, the entire population, and patients with previous time on HD therapy less than 5 and 3 years. Kaplan-Meier was subsequently applied to the entire population stratified by sex and variables found significant in the Cox analysis (diabetes, age, and calcitriol treatment). For stratification by age, patients were considered young or old when their ages were younger or older than the mean (62 years), respectively. The period of observation was 4 years (January 1996 to January 2000). We used log-rank test to determine whether survival differences among the three BsmI genotypes were statistically significant.
RESULTS
After 4 years of follow-up, 83 patients (58%) were alive. Table 2 shows the distribution of genotype, allele, and haplotype frequencies for the three polymorphic markers of the VDR locus in the HD population, survivors, nonsurvivors, and the control group. FokI and BsmI polymorphisms were in Hardy-Weinberg equilibrium in the control and HD populations. Poly-A polymorphism was in Hardy-Weinberg equilibrium in the con- Table 3 .
Analysis of patients on calcitriol therapy (n ϭ 114) gave similar results, showing the following covariables to be significant: BB genotype NOTE. All models included as covariables: BsmI, FokI, and poly-A polymorphisms; calcitriol treatment; phosphorus, calcium, PTH, and albumin levels; sex; age; ischemic heart disease; diabetes; hepatitis C antibodies; time on HD therapy; and Kt/V. Cox model 1 was applied to all patients. Model 2 included patients who had been on HD therapy for less than 5 years, and model 3 included patients who had been on HD therapy less than 3 years.
Abbreviation: HCV, hepatitis C virus; NS, not significant. Table 4 ). Table 1 lists demographic, biochemical, and clinical data; causes of death distributed by BsmI genotypes; and statistical significance obtained with univariate analysis. No significant differences were found among the three genotypes. However, there was a trend toward a greater prevalence of ischemic heart disease and death from cardiovascular cause among individuals with the BB genotype. Figure 1 shows survival in the BsmI genotypes by Kaplan-Meier analysis during the 4-year follow-up period. Figure 1A shows the entire HD population, and Fig 1B and C shows subgroups of patients on HD therapy for less than 5 and 3 years, respectively. Survival means for the total HD population were as follows: 1,290 days (95% CI, 1,187 to 1,392) for bb genotype, 1,148 days (95% CI, 1,026 to 1,269) for Bb genotype, and 959 days (95% CI, 764 to 1,155) for BB genotype (log-rank test for equality of survival distribution for the BsmI genotype, P ϭ 0.00). Survival means for patients on HD therapy less than 5 years were as follows: 1,267 days (95% CI, 1,133 to 1,400) for bb genotype, 1,119 days (95% CI, 962 to 1,400) for Bb genotype, and 927 days (95% CI, 698 to 1,156 days) for BB geno- NOTE. All models included as covariables: BsmI, FokI, and poly-A polymorphisms; calcitriol treatment; phosphorus, calcium, PTH, and albumin levels; sex; age; ischemic heart disease; diabetes; hepatitis C antibodies; time on HD therapy; and hours of Kt/V.
Abbreviations: HCV, hepatitis C virus; NS, not significant. type (log-rank test for equality, P ϭ 0.03). Survival means for patients on HD therapy less than 3 years were as follows: 1,332 days (95% CI, 1,206 to 1,457) for bb genotype, 1,045 days (95% CI, 853 to 1,237) for Bb genotype, and 1,018 days (95% CI, 767 to 1,269) for BB genotype (log-rank test for equality, P ϭ 0.02).
When Kaplan-Meier was applied to the entire population stratified by variables significant in the Cox analysis, other than BB and Bb genotypes, survival means were as follows stratifying by sex: men, bb, 1,343 days (95% CI, 1,236 to 1,450); Bb, 1,059 days (95% CI, 892 to 1,226); and BB, 914 days (95% CI, 645 to 1,184); and women, bb, 1,240 days (95% CI, 1,068 to 1,411); Bb, 1,291 days (95% CI, 1,133 to 1,488); and BB, 1,011 days (95% CI, 732 to 1,290; adjusted log-rank P ϭ 0.00). Survival means were as follows stratifying by diabetes: patients with diabetes, bb, 1,136 days (95% CI, 839 to 1,432); Bb, 995 days (95% CI, 747 to 1,244); and BB, 556 days (95% CI, 320 to 791); and patients without diabetes, bb, 1,333 days (95% CI, 1,234 to 1,431); Bb, 1,183 days (95% CI, 1,045 to 1,320); and BB, 1,086 days (95% CI, 867 to 1,305; adjusted log-rank P ϭ 0.00). Survival means were as follows stratifying by age group: young, bb, 1,416 days (95% CI, 1,333 to 1,499); Bb, 1318 days (95% CI, 1,160 to 1,475); and BB, 1,131 days (95% CI, 725 to 1,537); and old, bb, 1,205 days (95% CI, 1,049 to 1,360); Bb, 1,057 days (95% CI, 895 to 1,218); and BB, 903 days (95% CI, 685 to 1,120; adjusted log-rank P ϭ 0.00). Survival means were as follows stratifying by calcitriol treatment: calcitriol treatment, bb, 1,352 days (95% CI, 1,252 to 1,451); Bb, 1,162 days (95% CI, 1,029 to 1,296); and BB, 1,040 days (95% CI, 817 to 1,264); and no calcitriol treatment, bb, 1,144 days (95% CI, 909 to 1,380); Bb, 1,040 days (95% CI, 796 to 1,285); and BB, 641 days (95% CI, 338 to 1,081; adjusted logrank P ϭ 0.00).
DISCUSSION
This is the first study to show the influence of genetic factors on the mortality of HD patients. Our results show that BB and Bb genotypes of the BsmI polymorphism of the VDR gene worsen survival in HD patients more than other comorbid conditions repeatedly associated with increased risk for mortality in this population. [29] [30] [31] [32] [33] In addition, our data suggest that calcitriol treatment has a protective effect.
Until the present time, three polymorphic markers of the VDR gene with clinical expression have been described. One located in the 5Ј translated region (FokI) and two located in the 3Ј untranslated region of the VDR locus (BsmI and poly-A). The BsmI polymorphism has a different clinical expression in different populations. For this reason, it was speculated that the clinical associations found might be caused by a different polymorphism located in a nearby locus with which it could be in linkage disequilibrium in some ethnic groups. In particular, the poly-A polymorphism of the VDR locus was found to be in linkage disequilibrium with the BsmI polymorphism in different populations, 34 and recent results found a lower transactivation ability of the L allele of this polymorphism. 35 Therefore, it was hypothesized that poly-A might be the polymorphism responsible for those clinical associations.
The distribution of BsmI, FokI, and poly-A genotypes found in our control and total HD populations is consistent with those found in other white populations. In our population, FokI and BsmI are in linkage equilibrium, and there is no influence of FokI polymorphism on secondary hyperparathyroidism severity. 36 We did not find an influence of this polymorphism on mortality. Poly-A polymorphism is in strong linkage disequilibrium with BsmI in controls and patients, with bL and BS as the most common haplotypes. However, the poly-A polymorphism did not show an influence on mortality in this study, whereas BsmI did. This indicates that the BsmI polymorphism is a better marker for mortality than poly-A and excludes poly-A as responsible for differences in survival despite the existence of linkage disequilibrium between them.
There are two possible mechanisms by which the BsmI polymorphism could influence mortality: (1) by directly modifying VDR sensitivity or expression in target cells or (2) inducing differences in 1,25-dihydroxyvitamin D 3 levels.
Regulation of the PTH gene by 1,25-dihydroxyvitamin D 3 is VDR mediated. Modifications in the concentration of VDR in target organs result in amplification or dampering of its effect. 37 In the same way, the feedback mechanism for the regulation of 1-␣-hydroxylase is VDR mediated. For this reason, polymorphisms of the VDR might modify 1.25-dihydroxyvitamin-D 3 levels. Stampfer et al 38 found greater levels of 1,25-dihydroxyvitamin D 3 in the BB genotype in a population of 591 healthy individuals, and the same findings were reported in our previous study 25 of patients with varying degrees of chronic renal failure. In all events, the population on the present study has terminal chronic renal failure, with deficient production of endogenous calcitriol. This makes the observed effect unlikely to be caused by this mechanism.
Although the aim of the study is not to establish how genotype can induce differences in mortality, it is worth noting the differences in the incidence of death from cardiovascular origin and prevalence of ischemic heart disease among different genotypes. The prevalence of ischemic heart disease and death from cardiovascular causes in patients with the bb genotype is one half that of patients with the BB genotype.
The BsmI VDR gene polymorphism might influence cardiovascular morbidity and mortality through its relationship with hyperparathyroidism and calcium-phosphate metabolism or through a VDR-mediated effect of 1,25-dihydroxyvitamin D 3 on vascular smooth muscle cells and myocytes.
In chronic renal failure, it is well known that hyperparathyroidism and relative hypoparathyroidism are associated with calcium and phosphate imbalance, which predisposes to cardiac and vascular calcifications and may precondition greater mortality rates. In a recent large study, 29 serum phosphate level was found to be an independent predictor of mortality, whereas PTH level was not. In our population, there was no difference in phosphate levels among genotypes. Nevertheless, when patients with diabetes are excluded from analysis or patients on calcitriol therapy are analyzed separately, phosphate levels show an influence on survival. Hyperparathyroidism has been considered one of the manifestations of uremic syndrome. However, the study of Block et al 29 found only a weak association between PTH levels and mortality. It was previously shown that genotype influences PTH levels, 25,26,39,40 which might suggest that parathyroid function is involved in patient survival. Our patients were divided into three groups according to PTH levels to account for the bimodal effect of PTH level. Thus, those with oversuppressed PTH or severe hyperparathyroidism formed separate groups that could be expected to have greater mortality rates. However, survival was not affected by this variable when corrected for other comorbid conditions in Cox analysis.
Conversely, there is enough experimental evidence on the cardiovascular effects of calcitriol. 21, 22 Reduced VDR synthesis or sensitivity might hamper calcitriol effects and influence pathogenically important events that lead to increased mortality. There is little demonstration of beneficial effects of calcitriol at the clinical level. 23 However, this direct mechanism might be responsible for the differences in cardiovascular morbidity in our patients.
A relevant result of the present study is that calcitriol treatment was selected in all Cox models as a significant covariable. This is in keeping with results of a recent study that found an association between absence of calcitriol treatment and lower albumin levels in HD patients. 41 Albumin level is a widely recognized predictor of mortality in this population. 42 Therefore, this suggests that calcitriol treatment could improve survival. Despite the relatively small number of untreated patients, the importance of this result makes it mandatory to perform further studies that include larger control groups.
A limitation of the present study might be the inclusion of prevalent instead of incident HD patients. They had been on HD therapy for different times before enrollment. However, the influence of this parameter on survival was minimized by including it as a confounding variable in Cox analysis. In addition, those patients with a history of 3 and 5 or less years of HD therapy were analyzed separately. This subgroup of patients forms a more homogeneous population with steadier mortality rates per year. This approach was preferred to retrospective selection of incident cases because the latter would result in exclusion of patients who initiated HD therapy and died before genotyping; consequently, the distribution of genotypes in such a population might not be the same as in the total prevalent HD and control populations. However, it is noticeable that results obtained in the total population reproduce almost exactly those obtained in these subgroups. That is, BB and Bb genotypes are associated with greater mortality rates in any of the populations, regardless of previous time on HD therapy.
In conclusion, this study shows that BsmI and poly-A polymorphisms are in linkage disequilibrium in our control and hemodialysis populations. Despite this, BsmI influences survival in HD patients, whereas poly-A does not.This does not support the theory that poly-A may be responsible for clinical actions attributed to BsmI to date. The FokI polymorphism is in linkage equilibrium with BsmI and poly-A and shows no influence on survival. The greater prevalence of ischemic heart disease and death from this cause in patients with the BB genotype suggest that this could be the mechanism underlying differences in mortality. Therefore, further studies focused on investigating such association would be of interest.
